Filtered By:
Drug: Methotrexate
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 5114 results found since Jan 2013.
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients
Am J Trop Med Hyg. 2023 Aug 7:tpmd230205. doi: 10.4269/ajtmh.23-0205. Online ahead of print.ABSTRACTChikungunya fever is a global vector-borne viral disease. Patients with acute chikungunya are usually treated symptomatically. The arthritic phase may be self-limiting. However, many patients develop extremely disabling arthritis that does not improve after months. The aim of this study was to describe the treatment of chikungunya arthritis (CHIKA) patients. A medical records review was conducted in 133 CHIKA patients seen at a rheumatology practice. Patients were diagnosed by clinical criteria and confirmed by the presence ...
Source: Am J Trop Med Hyg - August 7, 2023 Category: Infectious Diseases Authors: Jos é Kennedy Amaral Clifton O Bingham Peter C Taylor Luis M Vil á Michael E Weinblatt Robert T Schoen Source Type: research
Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis
CONCLUSION: RA patients may experience mild to moderate liver inflammation due to the infiltration of T, B cells, and macrophages, and the action of ACPAs. This is independent of obesity or diabetes and linked to systemic inflammation, and disease activity levels. The negative effects of methotrexate on liver function could be restricted to the concomitant presence of cardiovascular risk factors.PMID:37544847 | DOI:10.1016/j.ejim.2023.08.002
Source: European Journal of Internal Medicine - August 6, 2023 Category: Internal Medicine Authors: I Arias-de la Rosa M Ruiz-Ponce L Cuesta-L ópez C P érez-Sánchez F Leiva-Cepas M D Gahete P Navarro R Ortega J Cordoba E P érez-Pampin A Gonz ález A J Lucendo E Collantes-Est évez Ch L ópez-Pedrera A Escudero-Contreras N Barbarroja Source Type: research
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research
Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment
CONCLUSIONS: The results from this study suggest that children who receive therapies not clinically established as ototoxic (i.e., methotrexate) may still be at a high risk of developing long-term hearing loss as a late effect. Due to the high incidence rate of hearing loss among patients with pediatric cancer, we recommend that audiologists be part of the late-effects care team. This study also demonstrates that patients with pediatric cancer treated with methotrexate should receive routine long-term auditory monitoring as part of their standard of care to detect and manage hearing loss early, minimizing adverse outcomes....
Source: American Journal of Audiology - August 2, 2023 Category: Audiology Authors: Brittney Moore Gabrielle Sheets Jordan Doss Ayesha Umrigar Michael Norman Zhide Fang Pinki Prasad Amanda Musso Sloane Clay Fern Tsien Source Type: research
What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
CONCLUSION: Flares are frequent when systemic treatment is withdrawn, and uveitis or joint injections could be related risk factors. In MTX and biologic-naïve patients, the frequency of flares occurred in more than half of patients, although they were less frequent when clinical remission lasted for > 1 year.PMID:37527855 | DOI:10.3899/jrheum.2022-1305
Source: J Rheumatol - August 1, 2023 Category: Rheumatology Authors: Juan Carlos Nieto-Gonz ález Daniel Clemente Garulo Alina Boteanu Laura Trives-Folguera Ant ía García-Fernández Pablo Gonz ález Navarro Juan Carlos L ópez Robledillo Indalecio Monteagudo-Sa éz Source Type: research
